MYND Life Sciences Inc. (MYNDF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 797.54 Thousand CAD | 21.93% |
| 2022 | 654.11 Thousand CAD | -75.51% |
| 2021 | 2.67 Million CAD | 3814784.29% |
| 2020 | 70.00 CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 771.34 Thousand CAD | -3.28% |
| 2024 Q3 | 719.71 Thousand CAD | 1.66% |
| 2024 Q2 | 707.94 Thousand CAD | -8.22% |
| 2023 Q1 | 548.76 Thousand CAD | -16.11% |
| 2023 FY | 797.54 Thousand CAD | 21.93% |
| 2023 Q4 | 797.54 Thousand CAD | 133.46% |
| 2023 Q3 | 341.62 Thousand CAD | -4.2% |
| 2023 Q2 | 356.6 Thousand CAD | -35.02% |
| 2022 Q1 | 1.88 Million CAD | -29.51% |
| 2022 FY | 654.11 Thousand CAD | -75.51% |
| 2022 Q4 | 654.11 Thousand CAD | -33.44% |
| 2022 Q3 | 982.77 Thousand CAD | -23.92% |
| 2022 Q2 | 1.29 Million CAD | -31.37% |
| 2021 Q1 | 2.32 Million CAD | 0.0% |
| 2021 FY | 2.67 Million CAD | 3814784.29% |
| 2021 Q3 | 1.22 Million CAD | -36.26% |
| 2021 Q4 | 2.67 Million CAD | 117.24% |
| 2021 Q2 | 1.92 Million CAD | -17.01% |
| 2020 FY | 70.00 CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 97.947% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 88.953% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.256% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 92.443% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.387% |
| Mesoblast Limited | 667.9 Million USD | 99.881% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1002.112% |
| Genus plc | 1.02 Billion USD | 99.922% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 41.286% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -59.816% |
| Marizyme, Inc. | 22.01 Million USD | 96.377% |
| ContraFect Corporation | 20.67 Million USD | 96.143% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -27.2% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -104.306% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -108.684% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 44.307% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 80.764% |
| MultiCell Technologies, Inc. | 126.22 USD | -631767.374% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 15.127% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.379% |
| EV Biologics, Inc. | 431.71 Thousand USD | -84.739% |
| Q BioMed Inc. | 3.51 Million USD | 77.314% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 97.733% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -3.49% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -205.248% |
| Biomind Labs Inc. | 73.81 Thousand USD | -980.403% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.828% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 97.343% |
| Skye Bioscience, Inc. | 11.94 Million USD | 93.321% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 75.927% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 70.96% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 59.271% |
| IMV Inc. | 31.33 Million USD | 97.455% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -16.009% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 69.363% |
| GB Sciences, Inc. | 103.44 Thousand USD | -671.005% |
| Alpha Cognition Inc. | 2.45 Million USD | 67.476% |
| HST Global, Inc. | 1526.00 USD | -52163.63% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Halberd Corporation | 10.13 Thousand USD | -7772.303% |
| Enzolytics Inc. | 361.7 Million USD | 99.78% |
| Resverlogix Corp. | 8.11 Million USD | 90.172% |
| Affymax, Inc. | 7.44 Million USD | 89.285% |
| SYBLEU INC | 330.46 Thousand USD | -141.337% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 57.53% |
| argenx SE | 4.54 Billion USD | 99.982% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 97.146% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.328% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -3400.913% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 91.088% |
| AVAX Technologies, Inc. | 7.37 Million USD | 89.189% |
| Zenith Capital Corp. | 7410.00 USD | -10663.063% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.976% |
| Ember Therapeutics, Inc. | 184.00 USD | -433347.283% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -147.833% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -205.146% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.821% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 44.953% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 73.636% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.487% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 14.054% |
| BioStem Technologies, Inc. | 14.56 Million USD | 94.522% |
| ONE Bio Corp. | 70.08 Million USD | 98.862% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1296.895% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -34425.671% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 19.274% |
| Agentix Corp. | 261.39 Thousand USD | -205.114% |
| LadRx Corporation | 2.3 Million USD | 65.443% |
| Cell Source, Inc. | 195.17 Thousand USD | -308.638% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -65.962% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -125.539% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -125.539% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1181.235% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -24.683% |
| Itoco Inc. | 1.4 Million USD | 43.036% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -733.753% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -652.399% |
| Kadimastem Ltd | 2.3 Million USD | 65.386% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -944.533% |
| CytoDyn Inc. | 11.13 Million USD | 92.838% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -457.832% |
| Mobile Lads Corp. | 52.00 USD | -1533636.538% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -4360.531% |
| Qrons Inc. | 420.00 USD | -189791.19% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -106.901% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -44.451% |
| Rebus Holdings, Inc. | 5000.00 USD | -15850.86% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -94.797% |
| International Stem Cell Corporation | 5.39 Million USD | 85.203% |
| Bioxytran, Inc. | 137.63 Thousand USD | -479.45% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 94.684% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 95.189% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -909.548% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 7.764% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 89.39% |
| Neutra Corp. | 2851.00 USD | -27874.149% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 97.539% |
| PureTech Health plc | 693.97 Million USD | 99.885% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 90.119% |
| IXICO plc | 15.84 Million USD | 94.966% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 90.37% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.228% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Cellectis S.A. | 333.99 Million USD | 99.761% |